More DTC Gene Test Firms Hit With FDA Untitled Letters
This article was originally published in The Gray Sheet
FDA recently sent untitled letters to three direct-to-consumer genetic testing firms asking them to seek clearance for their making medical claims.
You may also be interested in...
Device-practice attorneys provide tips and precautions for laboratories advertising and promoting non-cleared or unapproved molecular-based diagnostics, and avoiding enforcement.
The Google-backed firm's carrier screening assay for a rare disease called Bloom syndrome is the first DTC genetic test to achieve sign off from FDA. More importantly, the marketing authority was awarded in a manner that could significantly streamline the path to market for future DTC carrier-screening assays.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.